Loading cancer entity…
Loading cancer entity…
Clinical trials
3,385 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT02057640 | MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma | completed | Phase 1 / Phase 2 | 16 | Jason ValentOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT01503242 | 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 | 15 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT00861510 | A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies | completed | Phase 1 | 16 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 3, 2019 | clinicaltrials |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | completed | Phase 1 | 128 | AbbVieINDUSTRY | 1 | Nov 29, 2019 | clinicaltrials |
| NCT02189343 | Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | completed | Phase 1 | 16 | CelgeneINDUSTRY | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00652626 | Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function(RENAL) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00555100 | Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma | completed | Phase 1 | 15 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01568294 | Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma | completed | Phase 1 | 12 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01937442 | Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma | completed | Phase 1 | 7 | CelgeneINDUSTRY | 2 | Nov 12, 2019 | clinicaltrials |
| NCT00005792 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | completed | Phase 1 | 131 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00761722 | Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma(RACE) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00834665 | Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma | completed | Phase 1 | 59 | University of PennsylvaniaOTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT01142232 | Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma | completed | Phase 1 / Phase 2 | 60 | Attaya SuvannasankhaOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT02215967 | Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2019 | clinicaltrials |
| NCT00932698 | Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma | completed | Phase 1 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01001442 | Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 35 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01638936 | BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 64 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01372540 | Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | completed | Phase 1 | 76 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT02811822 | A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma | completed | Phase 1 | 10 | GlycoMimetics IncorporatedINDUSTRY | 4 | Jul 10, 2019 | clinicaltrials |
| NCT01830816 | Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment | completed | Phase 1 | 41 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 10, 2019 | clinicaltrials |
| NCT00916058 | Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 57 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT00697346 | Study of MLN8237 in Participants With Advanced Hematological Malignancies | completed | Phase 1 | 58 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | May 31, 2019 | clinicaltrials |
| NCT02426723 | Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients | completed | Phase 1 | 25 | JW PharmaceuticalINDUSTRY | 2 | May 17, 2019 | clinicaltrials |
| NCT00002787 | Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation | completed | Phase 1 | 22 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT00863174 | A Bioequivalence Study of SPARC_147709 in Patients With Multiple Myeloma | completed | Phase 1 | 24 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 0 | May 3, 2019 | clinicaltrials |
| NCT01246063 | Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT01521611 | Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy | completed | Phase 1 / Phase 2 | 62 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT01383928 | Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 64 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 21, 2019 | clinicaltrials |
| NCT01556438 | Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma | completed | Phase 1 | 16 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT02497378 | A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 8 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Mar 7, 2019 | clinicaltrials |
| NCT00520130 | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01440582 | Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients | completed | Phase 1 | 77 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2019 | clinicaltrials |
| NCT00943319 | Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies | completed | Phase 1 / Phase 2 | 50 | University of ChicagoOTHER | 1 | Feb 4, 2019 | clinicaltrials |
| NCT01634217 | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT01549431 | Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma | completed | Phase 1 | 32 | Emory UniversityOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT02240719 | Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | completed | Phase 1 | 20 | University of California, DavisOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT01645930 | Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Nov 8, 2018 | clinicaltrials |
| NCT01342289 | Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | completed | Phase 1 | 127 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT00231166 | Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 11, 2018 | clinicaltrials |
| NCT00024466 | Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01355705 | Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 14 | Michaela LiedtkeOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01272466 | Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Herlev HospitalOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT00701103 | Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) | completed | Phase 1 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT01428492 | Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma(PKB115125) | completed | Phase 1 | 90 | NovartisINDUSTRY | 5 | Aug 8, 2018 | clinicaltrials |
| NCT01690143 | Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT02071888 | Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors | completed | Phase 1 | 25 | Calithera Biosciences, IncINDUSTRY | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00001830 | Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | completed | Phase 1 | 110 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01129193 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | completed | Phase 1 | 44 | Amir MortazaviOTHER | 1 | Jun 4, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Dec 16, 2019source: clinicaltrials